Drugs / UTAA91 injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06982534 | Jun 2025 → Dec 2027 expected | systemic sclerosis | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UTAA91 injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06982534 ↗ |
| Modality | Cell therapy | “CAR-modified gamma delta T cells” NCT06982534 ↗ |